Biotech News

Catheter Precision to Change its Name and Ticker Symbol to Flyte Aviation and “VJET” and Effect 1-for-10 Reverse Stock Split, Monday, October 5, at Market Open

Catheter Precision (VTAK)Catheter PrecisionSEC filing

Changes highlight the Company’s growth trajectory as a leading private, regional jet aviation business

October 02, 2026 16:30 ET | Source: Catheter Precision, Inc.

FORT MILL, S.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (the “Company”), today announced its Board of Directors has approved changing its name and ticker symbol to Flyte Aviation, Inc. and “VJET,” respectively.

Additionally, the Company will effect a one-for-ten reverse stock split -- as had been approved by stockholders at a Special Meeting of Stockholders April 15, 2026. Every ten shares of common stock will be combined into one share, reducing the outstanding shares from approximately 21.0 million to approximately 2.1 million, with no change to the par value or authorized shares. The reverse stock split will not alter any stockholder’s percentage ownership interest, except for the treatment of fractional shares, and proportionate adjustments will be made to outstanding options, warrants and convertible preferred stock. Shares will begin trading with the new name and ticker, on a split-adjusted basis, effective at the opening of trading on Monday, October 5, 2026.The Company’s common stock remains listed on the NYSE American stock exchange and its new CUSIP number following the reverse stock split will be 74933X 807.

The name change highlights the Company’s growth trajectory as a leading private, regional jet aviation business.

Stockholders do not need to take any action. Whether the stockholders hold the Company’s common stock in physical certificate form, or at the transfer agent in book entry form, or at a broker dealer -- all shares will be automatically adjusted – the Company’s exchange agent will seamlessly adjust the shares accordingly at no cost to the stockholders. No fractional shares will be issued; stockholders who would otherwise be entitled to a fractional share will instead be entitled to receive their pro rata portion of the net proceeds from the aggregation and sale of such fractional shares by the Company’s exchange agent.

About Flyte Aviation, Inc.

Catheter Precision, Inc. (to be renamed Flyte Aviation, Inc. effective October 5, 2026), through its wholly-owned subsidiary Fly Flyte, Inc. (“Flyte”), is a technology-enabled private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient private air travel throughout the US and select international markets. Through its direct-to-consumer booking platform, standardized pricing on select routes, strategic partnerships, and FAA-certified Part 135 operating subsidiary Ponderosa Air, LLC, Flyte is delivering a faster and more convenient private aviation experience.

For more information, visit www.flyflyte.com .

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the expected timing and effects of the name change, ticker symbol change and reverse stock split, expected future growth, demand, strategic partnerships, market expansion, brand awareness, aircraft utilization and Flyte’s future operations, are forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially, including the risk that the reverse stock split may not have the intended effect on the market price or liquidity of the Company’s common stock. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for a discussion of these risks. Except as required by law, the Company undertakes no obligation to update any forward-looking statement.

Investor Contact [email protected]

Related news

VTAKCatheter Precision2026-10-05 08:15 EST

Flyte Aviation Launches Under NYSE American Ticker “VJET”

VTAKCatheter Precision2026-08-27 12:00 EST

Catheter Precision Achieves Major Commercial Milestones with Cardinal Health, Johns Hopkins and the placement of the First VIVO System in Germany

XAIRBeyond Air2026-08-25 11:00 EST

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments

ANGOAngioDynamics2026-10-02 10:00 EST

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

ANGOAngioDynamics2026-09-28 20:30 EST

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

ADPTAdaptive Biotechnologies2026-09-17 12:00 EST

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

TMCITreace Medical Concepts2026-09-15 21:07 EST

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting

FEMYFEMASYS2026-08-12 13:00 EST

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents

ICCMIceCure Medical2026-08-12 12:30 EST

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

IRTCiRhythm2026-08-06 20:06 EST

iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

Catheter Precision

Cardiac Electrophysiology and Aviation Company Catheter Precision develops products for cardiac electrophysiology and also owns private-aviation charter operations acquired through FLYTE. The company therefore operates through two distinct segments. VIVO Cardiac Mapping System VIVO is a non-invasive three-dimensional mapping system used...

Recent company news

Stock data

Close
0.15 USD
Market cap
2.58M USD
Exchange
NYSE
Sector
MedTech
Location
United States